Deals
Nestle Bets $2.6 Billion on Aimmune’s Peanut Allergy Treatment
- Renewed health push comes as demand for legacy products eases
- Nestle expects Aimmune’s therapy to turn into a blockbuster
This article is for subscribers only.
Nestle SA agreed to buy Aimmune Therapeutics Inc. for $2.6 billion, adding a promising peanut allergy treatment to its portfolio of coffee, snacks and water.
The Swiss owner of Nespresso will pay $34.50 a share for the U.S. biotech firm, almost triple its last closing price. Aimmune makes a therapy to help reduce allergic reactions to peanuts in children and teens by exposing them to tiny doses over time.